Channel
@medicine_oncology
On this record: Growth · Engagement · Posts · Polls · Citations · Cite this entry
18subscribers
+3 since we began measuring on 6 August 2026
Risers and fallers across the register · movement among entries of Under 1,000.
| Telegram ID | -1003621384603 |
|---|---|
| Type | Channel |
| Username | @medicine_oncology |
| Created | Between 1 December 2025 and 31 May 2026 — estimated from Telegram’s id allocation, not measured. How this range is calculated. |
| First recorded | 11 August 2026 |
| Last confirmed live | 12 September 2026 |
| Measurements held | 4 |
| Confirmed unchanged | 3 times, most recently 12 September 2026 |
| On Telegram | t.me/medicine_oncology |
| Measured (UTC) | Subscribers | Change |
|---|---|---|
| 28 Aug 2026, 03:55 | 18 | +2 |
| 21 Aug 2026, 04:45 | 16 | +1 |
| 11 Aug 2026, 22:45 | 15 | no change |
| 6 Aug 2026, 12:32 | 15 | first reading |
20 posts held, back to 18 June 2026 — the reader has not yet reached the start of this channel’s public history, so older posts may sit further back, unread. Read across 1 page of Telegram’s post history, 20 posts per page.
Nothing published in the last 30 days. ERR and ER are rolling 30-day measures, so there is nothing to compute — we hold 20 posts for this entry, the most recent from 7 August 2026. An engagement rate over an empty window would be a number about nothing.
🧠 Harvard 6th Annual Update in Neuro-Oncology 2026 📝 Course Overview: HARVARD MEDICAL SCHOOL • LIVE ONLINE • JULY 22-24, 2026 Harvard 6th Annual Update in Neuro-Oncology 2026 6th Annual Update in Neuro-Oncology 2026 — three days of Harvard Medical School neuro-oncology, from molecular neuropathology and WHO classification to the medical,... 💙 Edition: 2026 📁 Category: #Neurology #Harvard #Oncology 👇 Tap …
🎗️ MSKCC Immunotherapy Oncology 2026: Elite CME Course 📝 Course Overview: MSKCC Immunotherapy Oncology 2026 The MSKCC Immunotherapy Oncology 2026 is the Definitive resource for modern cancer treatment. This Elite program provides a comprehensive exploration of checkpoint inhibitors, CAR T-cell therapy, and bispecific agents. Masterclass Overview of the MSKCC Immunotherapy Oncology... 💙 Edition: 2026 📁 Category: #MS…
There is no radiographic suggestion of vascular involvement.
Shares as published. No per-option vote count is published by Telegram, so none is shown.
🎗️ Clinical Case Challenge 🏢 Brand: UWorld 📚 Source: Passmachine Oncology Qbank 📝 A 71-year-old man with longstanding chronic hepatitis B infection is found on an abdominal CT scan to have an 8 cm mass in the right hepatic lobe, with contrast enhancement characteristics consistent with hepatocellular carcinoma. There is no radiographic suggestion of vascular involvement. Serum AFP level is elevated at 680 ng/m ━━━━…
🎗️ Clinical Case Challenge 🏢 Brand: UWorld 📚 Source: Passmachine Oncology Qbank 📝 A 55-year-old woman with metastatic ovarian cancer has been on treatment with gemcitabine, is currently on cycle 8 of her chemotherapy, and has received cumulative dosing of 24,000mg/m2. She presents to the emergency room with shortness of breath and fatigue. On exam, her vital signs show a temperature of 38.0, heart rate of 110, blood…
Which one of the following Federation of Gynecology and Obstetrics stages would most likely be seen in this patient?
Shares as published. No per-option vote count is published by Telegram, so none is shown.
🎗️ Clinical Case Challenge 🏢 Brand: UWorld 📚 Source: Passmachine Oncology Qbank 📝 A 32-year-old female presents with a history of postcoital bleeding. A colposcopic examination is performed and features of a malignant cervix are seen. Although the lesion involves the upper portion of the vagina, clinical examination does not reveal involvement of any other structures. The patient recently had a biopsy which was cond…
🩸 UW Medicine Comprehensive Hematology & Oncology Review 2024 📝 Course Overview: UW Medicine Hematology & Oncology Review 2024 – High-Yield Home › Hematology › UW Medicine Hematology & Oncology Review 2024 High-Yield • Evidence-Based • Clinically Relevant UW Medicine Comprehensive Hematology & Oncology Review 2024 Format: HD video + PDF syllabus... 💙 Edition: 2024 📁 Category: #Board #Hematology #Oncology #UW_Medici…
Further evaluation of this patient is most likely to show which of the following findings?
Shares as published. No per-option vote count is published by Telegram, so none is shown.
🎗️ Clinical Case Challenge 🏢 Brand: UWorld 📚 Source: Passmachine Oncology Qbank 📝 A 48-year-old man presents to the clinic for the evaluation of an 8- month history of fatigue and profuse, watery, odorless diarrhea. He reports that he has had a 10.5 kg (23 lbs.) weight loss during this time. Physical examination shows conjunctival pallor and poor skin turgor. The lab report is attached. A CT scan of the abdomen with…
Which of the following is the most effective management?
Shares as published. No per-option vote count is published by Telegram, so none is shown.
🎗️ Clinical Case Challenge 🏢 Brand: UWorld 📚 Source: Passmachine Oncology Qbank 📝 A 66-year-old woman is brought to the emergency department after a witnessed seizure. She has a past history of primary CNS lymphoma, which has been successfully treated with high dose methotrexate 26 months ago. An urgent MRI of the brain shows hypointense, vivid homogeneous infiltrates in the periventricular white matter. Further stu…
Showing the 12 most recent of 20 posts we hold for @medicine_oncology. View and reaction counts are the latest single reading for each post, not a live figure, and a recent post is still accumulating both. A view count marked ≈ was rounded by Telegram before we ever saw it — t.me prints views in full below 1,000 and to three significant figures above, so ≈1,200,000 means somewhere between 1,150,000 and 1,249,999. Unmarked counts are exact. Text is reproduced from the public post preview and truncated for length.
The 6 most recent of 7 polls we hold for this entry, as Telegram rendered them when we read the post. A poll’s figures keep moving after that, so each one is dated.
There is no radiographic suggestion of vascular involvement.
Shares as published. No per-option vote count is published by Telegram, so none is shown.
Which one of the following Federation of Gynecology and Obstetrics stages would most likely be seen in this patient?
Shares as published. No per-option vote count is published by Telegram, so none is shown.
Further evaluation of this patient is most likely to show which of the following findings?
Shares as published. No per-option vote count is published by Telegram, so none is shown.
Which of the following is the most effective management?
Shares as published. No per-option vote count is published by Telegram, so none is shown.
Which of the following would be the most appropriate treatment?
Shares as published, totalling 99%. No per-option vote count is published by Telegram, so none is shown.
What do you recommend for her?
Shares as published, totalling 101%. No per-option vote count is published by Telegram, so none is shown.
Percentages only — there are no per-option vote counts here, because Telegram publishes none. The public post preview gives each option’s share and a single voter total, and nothing else. Multiplying one by the other would produce a per-option tally that looks measured and is not: the shares are rounded to whole numbers before we ever see them. We print what was published and leave the column that does not exist empty.
The shares need not add up to 100. Rounding alone puts many polls at 99 or 101. A poll that allows more than one answer per voter runs well past 100 by design, and several here do. The bars are drawn against a fixed 100% track at each option’s own percentage rather than normalised to the total, so a poll that exceeds it shows that it does instead of being quietly rescaled.
Read from the 20 most recent posts we hold, published 18 June 2026 to 7 August 2026. Telegram labels each poll by kind — an anonymous poll, a quiz, a closed set of final results — and that label is reproduced rather than paraphrased.
Republished by
Channels on the register that have forwarded this channel's posts into their own feed.
Built only from forwarded posts we have actually read, on both sides. Coverage is early and deliberately incomplete: a missing link means we have not read the post that would prove it, never that the relationship does not exist. Counts are distinct forwarded posts observed, so they only ever go up as we read more.
Named by 1 registered channel — every channel on the register whose own posts have named this one, by its current username or any other username it currently holds, merged from two separately captured readings of the same fact so a namer caught by only one of them is not missed and a namer both caught is not counted twice. A username this channel has since dropped is not matched — that handle may belong to someone else now, and crediting today’s namer to yesterday’s owner would misattribute it.
Named by
Channels on the register whose posts name this channel's handle.
A mention is a weaker signal than a forward and is counted separately for that reason — naming a channel is not republishing it, and a handle in a post body is easy to place deliberately. The post counts beside each row below are distinct posts in which the handle appeared, from posts we have read on both sides — the “Named by N registered channels” figure above is a different count, of distinct NAMING CHANNELS rather than posts, and is not the sum of the rows under it.
A live page changes as we take new readings, so a citation should name the measurement it is based on, not just the URL. The line below cites the subscriber count as measured 28 August 2026 — this entry's latest reading, not the date you are reading this.
“Oncology Resources | Medicine.ac” (@medicine_oncology), 18 subscribers as measured 28 August 2026. Telegram Register, tgregister.com/channel/medicine_oncology.
Full measurement history, CC BY 4.0. Every reading this register holds for this entry, not just the latest one, as a dated, downloadable record: CSV · JSON. Free to use with attribution to tgregister.com. Each file carries its own generation timestamp, which is the figure to cite for exactly when the data was retrieved.